Related content

A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy

By Berrak Su  

Supportive Care in Cancer, Vol. 15, Iss. 10, 2007-10 ,pp. : 1163-1168

Springer Publishing Company

Access to resources Recommend Favorite

Modulation of cisplatin pharmacodynamics by Cremophor EL - experimental and clinical studies

By Gelderblom H.   Loos W.J.   Verweij J.   van der Burg M.E.L.   de Jonge M.J.A.   Brouwer E.   Nooter K.   Stoter G.   Sparreboom A.  

European Journal of Cancer, Vol. 38, Iss. 1, 2002-01 ,pp. : 205-213

Elsevier

Access to resources Recommend Favorite

Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study

By Brain E.   Rezai K.   Weill S.   Gauzan M.   Santoni J.   Besse B.   Goupil A.   Turpin F.   Urien S.   Lokiec F.  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 375-381

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

By Banerjee S.   Rustin G.   Paul J.   Williams C.   Pledge S.   Gabra H.   Skailes G.   Lamont A.   Hindley A.   Goss G.   Gilby E.   Hogg M.   Harper P.   Kipps E.   Lewsley L-A   Hall M.   Vasey P.   Kaye S. B.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 679-687

Oxford University Press

Access to resources Recommend Favorite

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

By Bernsdorf Mogens  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 463-470

Springer Publishing Company

Access to resources Recommend Favorite